跳至主要内容
临床试验/NCT03251937
NCT03251937已完成不适用

VERITAS - A Study to Demonstrate the Value of Multiple Modalities Using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

Boston Scientific Corporation15 个研究点 分布在 1 个国家目标入组 97 人开始时间: 2018年1月9日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
97
试验地点
15
主要终点
Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline

研究概览

简要总结

To demonstrate the value of multiple modalities and sustained clinically significant pain relief in patients with chronic pain when using the Boston Scientific Spectra WaveWriter Spinal Cord Stimulator (SCS) System.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Chronic pain of the trunk and/or limbs
  • •22 years of age or older at time of enrollment
  • •Willing and able to comply with all protocol-required procedures and assessments/evaluations provided in English
  • •Willing and capable of giving informed consent

排除标准

  • •Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment, might confound reporting of study outcomes
  • •Significant cognitive impairment that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study
  • •Current systemic infection, or local infection in close proximity to the anticipated surgical field
  • •Breast-feeding, pregnant or planning to get pregnant during the course of the study or not using adequate contraception
  • •Previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator)
  • •Participating, or intends to participate, in another clinical trial that may influence the data that will be collected for this study

研究组 & 干预措施

Spinal Cord Stimulation

Experimental

Spectra WaveWriter SCS System

干预措施: Spectra WaveWriter SCS System (Device)

结局指标

主要结局

Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline

时间窗: 3 months post activation

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验